Albumin is a remarkable carrier protein with multiple cellular receptor and ligand binding sites, which are able to bind and transport numerous endogenous and exogenous compounds. The development of albumin-bound drugs is gaining increased importance in the targeted delivery of cancer therapy. Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal metastasis (PM). PM is characterized by the presence of widespread metastatic tumor nodules on the peritoneum, mostly originating from gastro-intestinal or gynaecological cancers. Albumin as a carrier for chemotherapy holds considerable promise for IP delivery in patients with PM. Data from recent (pre)clinical trials suggest that IP albumin-bound chemotherapy may result in superior efficacy in the treatment of PM compared to standard chemotherapy formulations. Here, we review the evidence on albumin-bound chemotherapy with a focus on IP administration and its efficacy in PM.

中文翻译：

---

用于腹膜内给药的基于白蛋白的癌症治疗剂：综述。

白蛋白是具有多个细胞受体和配体结合位点的引人注目的载体蛋白，其能够结合和运输许多内源性和外源性化合物。与白蛋白结合的药物的开发在靶向治疗癌症中越来越重要。腹膜内（IP）药物递送是局部治疗腹膜转移（PM）的一种有吸引力的策略。PM的特征是腹膜上存在广泛的转移性肿瘤结节，这些结节主要源于胃肠道或妇科癌症。白蛋白作为化学疗法的载体在PM患者IP传输方面具有广阔的前景。来自最近（临床前）临床试验的数据表明，与标准化疗方案相比，结合IP白蛋白的化疗可能在PM的治疗中产生更高的疗效。在这里，我们审查有关白蛋白结合化疗的证据，重点是IP管理及其在PM中的疗效。